TY - JOUR
AU - Liu, Xinxue
AU - Shaw, Robert H.
AU - Stuart, Arabella S.V.
AU - Greenland, Melanie
AU - Aley, Parvinder K.
AU - Andrews, Nick
AU - Claire Cameron
AU - Charlton, Sue
AU - Clutterbuck, Elizabeth A.
AU - Collins, Andrea M.
AU - Dinesh, Tanya
AU - England, Anna
AU - Faust, Saul N.
AU - Ferreira, Daniela M.
AU - Finn, Adam
AU - Green, Christopher A.
AU - Hallis, Bassam
AU - Heath, Paul T.
AU - Hill, Helen C.
AU - Lambe, Teresa
AU - Lazarus, Rajeka
AU - Libri, Vincenzo
AU - Long, Fei
AU - Mujadidi, Yama F.
AU - Plested, Emma
AU - Provstgaard-Morys, Samuel
AU - Ramasamy, Maheshi N.
AU - Ramsay, Mary E.
AU - Read, Robert C.
AU - Robinson, Hannah
AU - Singh, Nisha
AU - Turner, David P. J.
AU - Turner, Paul J.
AU - Walker, Laura
AU - White, Rachel
AU - Nguyen-Van-Tam, Jonathan S.
AU - Snape, Matthew D.
AU - Com-COV Study Group
PY - 2021
DA - August
TI - Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
JO - The Lancet
EP - 869
VL - 398
IS - 10303
DO - https://doi.org/10.1016/S0140-6736(21)01694-9
AB - Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer–BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.
PB - Elsevier
UR - https://publichealthscotland.scot/id/42328
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER